Skip to main content
OpenTrials
Completed

NCT Number: NCT04679272

Prognostic Evaluation of COVID-19 in Rheumatoid Arthritis Patients

COVID-19 is an infectious disease caused by SARS-CoV2 virus. The objective of our study is to analyze the progression and the severity of COVID-19 in patients with RA. Indeed, few data are available on this subject, and this would allow us to improve management of COVID-19 in these potential at-risk patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Covid19 Arthritis Arthritis, Rheumatoid Autoimmune Diseases COVID-19 Connective Tissue Diseases Coronaviridae Infections Coronavirus Infections Immune System Diseases Infections Joint Diseases Lung Diseases Musculoskeletal Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Rheumatic Diseases Rheumatoid Arthritis Skin and Connective Tissue Diseases Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

UH Montpellier

Montpellier, 34295, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Confirmed COVID-19 diagnosis (positive PCR or serology) in RA patients or healthy controls.

Exclusion criteria

  • Age under 18 years old
  • Suspected COVID-19 diagnosis (typical symptoms without a positive PCR or serology)

Treatment and study plan

Primary outcomes

  1. Hospitalization rates for COVID-19

    Time frame: 1 day

    Proportion of hospitalized patients in RA group or control group. From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.

Secondary outcomes

  1. Critical care transfer rate for COVID-19 and death due to COVID-19

    Time frame: 1 day

    Proportion of patients transferred in critical care for COVID-19 or deaths due to COVID-19 From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.

  2. Pulmonary comorbidities, corticosteroids or DMARDs use

    Time frame: 1 day

    Type and severity of patients pulmonary comorbidities and treatment by corticosteroids or DMARDs in RA group From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.

  3. Age

    Time frame: 1 day

    Patients demographics From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.

  4. Number of Participants with co-morbidities

    Time frame: 1 day

    Patients comorbidities From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.

  5. Type of clinical presentation

    Time frame: 1 day

    Patients COVID-19 clinical presentation From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.

  6. Type of associated treatments

    Time frame: 1 day

    From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.

Sponsors and collaborators

Lead sponsor

University Hospital, Montpellier

Other

Registry information

Official study title

Prognostic Evaluation of COVID-19 in Rheumatoid Arthritis Patients : ProCOVRA

Acronym: ProCOVRA

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Dec 22, 2020
Registry last updated
Mar 1, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.